R&D JP Morgan 2024 – Katherine Stueland Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
